Valeo Pharma announced today that it closed an upsized private placement worth more than $6.6 million. Montreal, Canada-based Valeo issued 6,645 unsecured, non-convertible debenture units at a purchase price of $1,000 per unit, totaling gross proceeds of $6.645 million, according to a news release. Each debenture unit consists of one unsecured non-convertible debenture in the […]
Valeo Pharma
Valeo Pharma signs Canadian commercialization deal with Novartis
Valeo Pharma announced today that it entered into a commercialization and supply agreement with Novartis Canada for its asthma therapies. Montreal-based Valeo’s deal is to offer Canadian commercialization efforts for two asthma therapies: Enerzair Breezhaler (indacaterol as acetate, glycopyrronium as bromide and mometasone furoate, and Atectura Breezhaler (indacaterol as acetate and mometasone fuorate). Under the […]
